David Fredrickson: Yes, absolutely. So first of all, we’re quite pleased with the current performance of, let’s say, our new portfolio of products Breztri, Fasenra and Tezspire. And we need to realize that all those products have clear lifecycle management opportunities. The growth of all those products is already quite impressive, and especially the U.S launch of Tezspire is very hopeful. But we’re doing a study with Breztri in asthma, we are doing a study with for Fasenra in COPD, and are multiple other lifecycle management initiatives ongoing to further expanse the indications for Tezspire. Of all the therapeutic areas, I feel extremely comfortable that the R&I portfolio will see very strong growth. The moment we have digested the patent loss of Symbicort and the ongoing loss of Pulmicort in China, but we are very, very positive about the outlook of our respiratory portfolio. Mene?
Menelas Pangalos: And just to add the molecules that you haven’t mentioned, we’ve got tozorakimab, our IL-33 that’s in late stage development for COPD. But also we’ll be moving forwards in asthma and acute respiratory failure as well. We have our inhaled biologics which are moving, we have an oral flap, which is really interesting. And I think when you look at the wealth of data, I think we’re very well-positioned not just with the molecules that we have today, but also the molecules and obviously, PT027 as well. The outcome yesterday was something that we view as positive. We had a good outcome, and look forward to talking to regulators about the populations that we will treat as we move forward.
Pascal Soriot: It’s important with PT027 by the way to. Remember this is the first time something like this is recommended in the United States. It’s a big change and the potential is there. But as you heard from the ups and downs, of course, here PT027, Breztri still Fasenra, Tezspire will drive growth. But on the other hand, Symbicort is affected, Symbicort is declining. So over the next few years, I think it’s fair to expect that this franchise may not go over the near-term as much as the oncology. But it gives me a chance to make a point here, which I often internally make with people, I like cycling and when you cycle that if you are the back of the pack, you consume 30%, 40% less energy. And a few years ago, oncology was at the back of the pack and today oncology is the front of the pack and we are a business where we basically rotate and the goals will come from different franchises at different period of times, and that’s the strength of our company, not only the geographical footprint.
China drove growth over the last few years. In the last couple of years, it’s going through its own patent transition, it will go again. In the meantime, Europe, U.S., Japan are growing quite a lot. Oncology is growing. Respiratory a bit less, but respiratory was growing a lot before it will go again. We have a strong pipeline. And that’s really what we have to offer. This diversity of geographies and diversity of products and portfolio, which gives a certain stability and predictability to the overall company. And of course, now we’re not a company that is in specialty care in the U.S with very, very high operating margins. We are targeting an improvement in operating margin, but what we have to offer is top line leading growth rates and also a sudden stability of our company.
On the tax rate, Aradhana?
